Kaposi sarcoma (KS) is a locally progressive, intermediate-grade vascular neoplasm with no
known cure, high recurrence rates, and potential for wide dissemination. Low efficacy and
high toxicity limit current therapeutic options for advanced disease. Activation of mammalian
target of rapamycin (mTOR), platelet-derived growth factor (PDGF), vascular endothelial
growth factor (VEGF), and c-kit signaling pathways has been implicated in KS pathogenesis
and may suggest a role for targeted inhibitors. KS cases were retrospectively retrieved (N …